Meredith Cook Sells 400 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $59.54, for a total transaction of $23,816.00. Following the sale, the vice president now owns 83,478 shares of the company’s stock, valued at $4,970,280.12. This trade represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Meredith Cook also recently made the following trade(s):

• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total transaction of $21,568.00.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP traded down $0.10 during trading hours on Tuesday, reaching $58.82. The company’s stock had a trading volume of 140,306 shares, compared to its average volume of 182,678. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -106.94 and a beta of 0.74. The firm’s 50-day moving average price is $56.98 and its 200-day moving average price is $58.23.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. boosted its position in shares of ANI Pharmaceuticals by 149.7% during the third quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company’s stock worth $11,107,000 after acquiring an additional 111,613 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in ANI Pharmaceuticals by 3.9% in the 3rd quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock worth $477,000 after purchasing an additional 300 shares in the last quarter. State of Alaska Department of Revenue boosted its holdings in shares of ANI Pharmaceuticals by 5.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock valued at $564,000 after purchasing an additional 464 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of ANI Pharmaceuticals by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 1,582 shares in the last quarter. Finally, New York State Teachers Retirement System grew its position in shares of ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

ANIP has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.